Working group by Japan atherosclerosis society for making guidance of familial hypercholesterolemia. Guidelines for diagnosis and treatment of familial hypercholesterolemia 2017
-
- Harada-Shiba Mariko
- Department of Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute
-
- Arai Hidenori
- National Center for Geriatrics and Gerontology
-
- Ishigaki Yasushi
- Department of Internal Medicine Division of Diabetes and Metabolism, Iwate Medical University
-
- Ishibashi Shun
- Division of Endocrinology and Metabolism, Jichii Medical University School of Medicine
-
- Okamura Tomonori
- Department of Preventive Medicine and Public Health, School of Medicine, Keio University
-
- Ogura Masatsune
- Department of Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute
-
- Dobashi Kazushige
- Department of Pediatrics, Showa University School of Medicine
-
- Nohara Atsushi
- Kanazawa University Health Service Center
-
- Bujo Hideaki
- Department of Clinical-Laboratory and Experimental-Research Medicine, Toho University Sakura Medical Center
-
- Miyauchi Katsumi
- Department of Cardiology, Juntendo Tokyo Koto Geriatric Medical Center
-
- Yamashita Shizuya
- Department of Community Medicine & Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine
-
- Yokote Koutaro
- Department of Clinical Cell Biology and Medicine, Chiba University Graduate School of Medicine
書誌事項
- タイトル別名
-
- Guidelines for Diagnosis and Treatment of Familial Hypercholesterolemia 2017
- Working Group by Japan Atherosclerosis Society for Making Guidance of Familial Hypercholesterolemia: Guidelines for diagnosis and treatment of familial hypercholesterolemia
- Guidelines for diagnosis and treatment of familial hypercholesterolemia
この論文をさがす
説明
<p>Statement</p><p>1. Familial hypercholesterolemia (FH) is an autosomal hereditary disease with the 3 major clinical features of hyper-LDL-cholesterolemia, premature coronary artery disease and tendon and skin xanthomas. As there is a considerably high risk of coronary artery disease (CAD), in addition to early diagnosis and intensive treatment, family screening (cascade screening) is required (Recommendation level A) </p><p>2. For a diagnosis of FH, at least 2 of the following criteria should be satisfied:</p><p>① LDL-C ≥180 mg/dL, ② Tendon/skin xanthomas, ③ History of FH or premature CAD within 2nd degree blood relatives (Recommendation level A) </p><p>3. Intensive lipid-lowering therapy is necessary for the treatment of FH. First-line drug should be statins. (Recommendation level A, Evidence level 3) </p><p>4. Screening for CAD as well as asymptomatic atherosclerosis should be conducted periodically in FH patients. (Recommendation level A) </p><p>5. For homozygous FH, consider LDL apheresis and treatment with PCSK9 inhibitors or MTP inhibitors. (Recommendation level A) </p><p>6. For severe forms of heterozygous FH who have resistant to drug therapy, consider PCSK9 inhibitors and LDL apheresis. (Recommendation level A) </p><p>7. Refer FH homozygotes as well as heterozygotes who are resistant to drug therapy, who are children or are pregnant or have the desire to bear children to a specialist. (Recommendation level A) </p>
収録刊行物
-
- Ｊｏｕｒｎａｌ ｏｆ Ａｔｈｅｒｏｓｃｌｅｒｏｓｉｓ ａｎｄ Ｔｈｒｏｍｂｏｓｉｓ
-
Ｊｏｕｒｎａｌ ｏｆ Ａｔｈｅｒｏｓｃｌｅｒｏｓｉｓ ａｎｄ Ｔｈｒｏｍｂｏｓｉｓ 25 (8), 751-770, 2018-08-01
一般社団法人 日本動脈硬化学会
